Objective: This study employs the concept of relational autonomy to understand how relational encounters with family members (FMs) and care providers may shape decisions around ovarian cancer patients' clinical trial (CT) participation. The study also offers unique insights into how FMs view patients' decision making.
| INTRODUC TI ON
Potential research participants in clinical trials (CTs) must be informed of their right to self-determination and be provided an in-depth description of foreseeable benefits, risks of the trial and alternatives to participation as part of the process of informed consent. 1 Rational decision models and shared decision-making approaches focus on the individual patient's autonomy in CT decision making. [2] [3] [4] [5] However, social circumstances, including experiences, education, relationships and racial and cultural identification, all of which inform one's selfhood and therefore one's decision making, may result in departures from idealized, standardized or anticipated decision processes. 6 Indeed, reports indicate that the process by which patients with cancer make CT participation decisions is diverse and poorly understood. 6, 7 The decision-making process itself can be viewed as a "silent factor" in CT decision making, although much of the literature assumes shared decision making among patients, providers and family members (FMs) is preferred. 6 Research on ethical CT presentation highlights the need to enhance patients' autonomy by meeting ethical obligations and reforming informed consent processes so that they are an ongoing interactive process that prioritizes patients' privacy as well as creates opportunities for patients to interact with their social network. 2, 4, 5, 8, 9 Understanding how patient's autonomy is enacted is significant to the broader CT participation literature as it can inform efforts that seek to optimize trial enrolment among patients with cancer. However, there has been little focus on how patients' autonomy is embedded within family involvement in treatment decision making. [10] [11] [12] [13] Illness is not an isolated event that occurs at the individual level, but rather it can be a challenging circumstance that evolves from a family's history, and which can impact its future.
The objective of this research was to understand the social and familial contexts that shape cancer patients' and their family members' decision to enrol in a CT focusing on how family and other social engagement promote patients' overall agency. Specifically, we set out to understand patients' perceptions of their experiences around who, when and how others are engaged in CT decision making, and how those interactions shape their decisions, as well as how FMs perceive their own participation. As a guiding concept, we employ the relational autonomy (RA) theory 14 to understand these relational and social engagements. Relational autonomy is an umbrella term for a feminist reconfiguration of traditional notions of autonomy which are based upon a fixed, unchanging, independent and rationalistic conceptualization of an individual selfhood. 14, 15 Within traditional notions of autonomy, informed consent and clinical decision making are viewed as an individual and rational exercise free from the influence of others. [2] [3] [4] Instead, RA casts the individual's selfhood as iteratively shaped by, experienced and produced through interconnected relationships with others, and through the individual's own biography, emotions and social experiences. 14, 15 Personal autonomy, therefore, is realized through a dy- 23 This presents an opportunity to explore the topic of autonomy in decision making-which is portrayed as rational model-in the context of a lethal disease where patients are faced with decisions that impact both their medical and social situation.
| ME THOD

| Research approach
This study used an applied qualitative health research approach 24 focusing on patients' and FMs' perspectives on their experiences around decision making in CT participation and how findings could be applicable in CT enrolment decisions. We used an integrated approach of applied thematic analysis 25, 26 which involves a combination of inductive (themes emerging from participant's responses) and deductive (constructs from RA) coding. All participants provided informed consent and were assured of anonymity and confidentiality.
Ethics approval was obtained prior to initiating the study.
| Recruitment and data collection
The data for this study were collected from January 2012 through December 2014. Specific procedures surrounding methods and recruitment have been previously reported. 27, 28 We used a purposeful sampling approach. 29 Eligible patients had a diagnosis of ovarian cancer (epithelial ovarian carcinoma, primary peritoneal carcinoma or fallopian tube cancer), had been offered a CT (at one of two comprehensive cancer centres in the Midwest of the USA) and were willing to nominate at least one FM to participate in a separate interview. Nominated FMs were contacted to participate in an interview subsequent to enrolling the patient. Family members included biological and social relatives.
Data were gathered using a semi-structured interview guide. 
| Analysis
In an integrated approach, we began with an inductive analysis 25, 26, 30 to identify major themes. Inductive data analysis was conducted by 
| RE SULTS
Participant characteristics have been reported earlier. 27, 28 Briefly, a total of 72 participants (33 patients with ovarian cancer and 39
FMs) were interviewed across both study sites. Patients' mean age was 59 ± 9.9 (range 36-76). Seventy percent (n = 23) of patients were married or in a relationship, and 30% were never married, widowed, separated or divorced (n = 10). More than half (58%) were not working for pay (n = 19), and 55% had a bachelor's degree or higher (n = 18). The vast majority of the patient sample (94%, n = 31) selfidentified their race/ethnicity as White, non-Hispanic.
The majority (59% n = 23) of FMs was female. FMs identified as spouses/partners (33%, n = 13), adult children (23%, n = 9), siblings (15%, n = 6), parents (8%, n = 3), friends (15%, n = 6), niece (<1%, n = 1) and daughter-in-law (<1%, n = 1). FMs' mean age was 56.0 ± 13.4 (range 25-81); 59 percent had a bachelor's degree or higher (n = 23). More than half (54%, n = 21) were working full time;
22 percent (n = 28) were married or in a relationship, and 28% were never married, widowed, separated or divorced (n = 9). All FMs selfidentified their race/ethnicity as White, non-Hispanic. Ultimately, patients make decisions regarding whether or not to participate in a CT that are informed by multiple relationships, which is discussed in the third theme "maintaining the final say."
| Relational engagement in CT decisions among patients with ovarian cancer
As Sherwin 14 For many patients, the decision to enrol in a CT was based on knowledge acquired from physicians, and in some cases, information about the trial was presented as a recommendation to participate.
Doctors' comments that were reported by patients in the interviews such as, "you would be a good candidate for it," "there is a silver lining in here" and "it's a great idea" were identified by patients as powerful in shaping their CT participation decisions. 
| Familial roles and perceptions of the patient's decision
This theme considers how FMs perceive their role in the CT participation decision process and how they view patients' autonomous decision making. Some FMs positioned themselves as passive while others saw themselves as active in the decision-making process.
When asked about how much control they had over the final decision, most of them said they had none, although they noted that they were comfortable with the decision made by the patient.
FMs in our study largely confirmed that the ultimate decision rests with the patient, especially in the light of their realization that the patient is the one who will bear the burden of trial participation, including potential side-effects. Family members reported considering factors such as travel and cost, but they also spoke about a desire to make any concessions that would benefit the patient.
Some FMs talked about their passivity being a precaution against negative outcomes of the CT and the potential for regret. Other
FMs reported that they were willing to provide their opinions but that the patient was independent enough to make a decision. 
And he has a network of his own. [1b, male spouse]
FMs also reported that the trials were often presented in such a way that they felt their decision making was constrained by the reality of the disease progression and the limited available options for the patient. This perspective was described as curtailing any other factors weighing on their decision making. FMs were aware of how they might influence patients' decisions and created boundaries around their engagements. While most FMs perceived patients' decisions as being independent of them, their engagement in the decision-making process emphasizes a relational approach to autonomy.
I guess, you know, even if I don't get a warm fuzzy from
| Maintaining the final say
Both patients with ovarian cancer and FMs maintained that patients have the final say on whether or not to participate in a CT. Some patients perceived that CT participation decisions were self-generated: Clinical trials were often presented alongside other treatment options, and the initial presentation for some patients was at the time when their provider was asking them to decide a course of care, for example, at the first appointment following a surgery.
"I didn't wait for someone to tell me… I kind of made this one on my own. I don't know if it is the right or the wrong decision, but I was kind
Furthermore, patients who travelled to the clinic from a greater distance described the need to make a decision while they were at the clinic because that decision would trigger a blood draw, medication order or test that needed to be completed before they left for home. Finally, two participants in this study described negative experiences from taking information home for reflection and discussion with family. By the time those patients made a decision to participate, the trial slots were no longer available. These experiences thus shaped those patients' subsequent views on the trial decision-making process and the factors that influence autonomous decision making.
| D ISCUSS I ON
This study explored how social and familial contexts shape CT participation decisions among patients with ovarian cancer. Using RA as a guiding concept, we identify CT participation decision making as a complex relational process shaped by patients' engagement with health-care providers, FMs and friends, and informed by patients' broader social history and contemporary social context. Our findings are suggestive that, rather than viewing autonomy as having independence from extraneous influences and simply having the capacity to act with intent, 31 autonomy is both mediated and constituted by relational, familial, social, structural and situational dimensions and, thus, should be valued as such. 14, 15, 32 In the health-care domain, decisions are considered autonomous if patients are competent, have adequate information and understanding, and are free from explicit coercion. [2] [3] [4] [5] 14 This understanding of autonomy limits the social conditions that structure patients' selfhood, autonomy and subsequent decision making. A relational view of autonomy focuses not only on the particular decision being considered but also on how the decision relates to an individual's sense of self, and how they view themselves in the context of decision making. Patients in this study reflected on their personal philosophies, characteristics and life-experiences as contributing to CT participation decision making. They also drew on the experiences of other patients with cancer to facilitate or justify their decisions to participate in a CT, as has been established elsewhere. [33] [34] [35] [36] In a relational approach, autonomy is known to occur within and as a result of relationships and interactions [14] [15] [16] 36 Within this web of interactions, there were varying levels of influence, and patients were selective as to who, how, and when to engage others. The aim of this study was to understand the views of patients and FMs, but congruent with other reports, 6, [37] [38] [39] There is little empirical evidence about FM involvement in medical decision making, 13 and concerns about patient autonomy may arise if FM beliefs differ from those of patients. 42 Yet even in times of disagreement with FMs, patients described relationally informed decision-making behaviours. providers' perspectives on patients' CT decision making to understand how this coincides with patient and FM perspectives on health-care provider influence. Despite these limitations, our study is significant; notably, the inclusion of the FM perspective serves to contextualize our assertion that efforts to understand CT participation decision making must be attentive to the importance of the relational context in which disease is experienced.
| CON CLUS ION
The findings of this study suggest that the concept of autonomy in health care in general, and CT participation decision making in particular, should consider the relational contexts, disease factors, health-care system and CT design factors that shape patient decisions. Central to decision making is that patients reflect on their own and others' views when they consider trial participation. Interactions between patients and their FMs as well as how patients interpret/ understand health-care providers' recommendations for CT are important in patients' decisional autonomy.
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